876138-04-4Relevant academic research and scientific papers
A kind of deuterium generation 3-cyano-quinoline compound, a pharmaceutically acceptable composition, preparation method and its use
-
Paragraph 0105; 0106; 0115; 0116, (2016/10/17)
Disclosed in the invention are a deuterated 3-cyano quinoline compound or pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers, tautomers, polymorphic substances, metabolites etc., and a pharmaceutical composition containing such compounds, and the use of these compounds or compositions in the preparation of drugs for treating or preventing tumours, especially drugs such as protein kinase inhibitors. Compared with the prior art, the compounds of the present invention have the clear advantages of properties such as plasma drug concentration, half-life, clearance, microsomal stability, bioavailability or enzyme inhibition and the like, and thus can more effectively inhibit the activities of more than one protein kinase and/or inhibit the growth of tumuor cells.
4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted -amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
-
Page/Page column 10, (2008/06/13)
This invention relates to compounds having the structure of Formula I wherein R1, R2, R3, and R4 are described herein.
Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles
Boschelli, Diane H.,Wu, Biqi,Ye, Fei,Wang, Yan,Golas, Jennifer M.,Lucas, Judy,Boschelli, Frank
, p. 7868 - 7876 (2007/10/03)
Compound 1 (SKI-606, bosutinib), a 7-alkoxy-4-[(2,4-dichloro-5- methoxyphenyl)amino]-3-quinolinecarbonitrile, is a potent inhibitor of Src kinase activity. We previously reported that analogs of 1 with thiophene groups at C-7 retained the Src activity of
